Cargando…

Visceral leishmaniasis-hepatitis B/C coinfections: a rising necessity to triage patients for treatment

BACKGROUND AND OBJECTIVES: Visceral leishmaniasis (VL) is a life-threatening infection caused by Leishmania species. In Sudan, VL is caused by L donovani. Most drugs used to treat VL, especially pentavalent antimony compounds (sodium stibogluconate, SSG), are potentially hepatotoxic. A number of fat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adam, Abubakr O. A., Dafalla, Mohamed M. M., Mohammed, Hatim A. A., Elamin, Mohamed Y., Younis, Brima M., Elfaki, Mona E. E., Musa, Ahmed M., Elhassan, Ahmed M., Khalil, Eltahir A. G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	King Faisal Specialist Hospital and Research Centre 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6074856/ https://www.ncbi.nlm.nih.gov/pubmed/24894783 http://dx.doi.org/10.5144/0256-4947.2014.143

Ejemplares similares

A clinical algorithm for triaging patients with significant lymphadenopathy in primary health care settings in Sudan
por: Khalil, Eltahir A.G., et al.
Publicado: (2013)

The Economic Burden of Visceral Leishmaniasis in Sudan: An Assessment of Provider and Household Costs
por: Meheus, Filip, et al.
Publicado: (2013)

Post-Kala-Azar Dermal Leishmaniasis: A Paradigm of Paradoxical Immune Reconstitution Syndrome in Non-HIV/AIDS Patients
por: Khalil, Eltahir Awad Gasim, et al.
Publicado: (2013)

Insights into the possible role of IFNG and IFNGR1 in Kala-azar and Post Kala-azar Dermal Leishmaniasis in Sudanese patients
por: Salih, Mohamed A M, et al.
Publicado: (2014)

Treatment-Based Strategy for the Management of Post-Kala-Azar Dermal Leishmaniasis Patients in the Sudan
por: Musa, A. M., et al.
Publicado: (2013)

Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study
por: Musa, Ahmed M., et al.
Publicado: (2010)

Misdiagnosis and Mistreatment of Post-Kala-Azar Dermal Leishmaniasis
por: El Hassan, Ahmed Mohamed, et al.
Publicado: (2013)

Blood Parasite Load as an Early Marker to Predict Treatment Response in Visceral Leishmaniasis in Eastern Africa
por: Verrest, Luka, et al.
Publicado: (2021)

Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial
por: Omollo, Raymond, et al.
Publicado: (2011)

Y Chromosome Lineage- and Village-Specific Genes on Chromosomes 1p22 and 6q27 Control Visceral Leishmaniasis in Sudan
por: Miller, E. Nancy, et al.
Publicado: (2007)

Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study
por: Dorlo, Thomas P C, et al.
Publicado: (2017)

Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan
por: Younis, Brima M., et al.
Publicado: (2021)

Safety and Efficacy of Single Dose versus Multiple Doses of AmBisome® for Treatment of Visceral Leishmaniasis in Eastern Africa: A Randomised Trial
por: Khalil, Eltahir A. G., et al.
Publicado: (2014)

Single-dose liposomal amphotericin B (AmBisome(®)) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial
por: Edwards, Tansy, et al.
Publicado: (2011)

Visceral Leishmaniasis and HIV Coinfection in East Africa
por: Diro, Ermias, et al.
Publicado: (2014)

Visceral Leishmaniasis and HIV Coinfection in the Mediterranean Region
por: Monge-Maillo, Begoña, et al.
Publicado: (2014)

Visceral Leishmaniasis and HIV Coinfection in Latin America
por: Lindoso, José Angelo, et al.
Publicado: (2014)

Visceral leishmaniasis and HIV coinfection: current perspectives
por: Lindoso, José Angelo Lauletta, et al.
Publicado: (2018)

Is Visceral Leishmaniasis the same in HIV-coinfected adults?
por: Henn, Guilherme Alves de Lima, et al.
Publicado: (2018)

LEISH2b - A phase 2b study to assess the safety, efficacy, and immunogenicity of the Leishmania vaccine ChAd63-KH in post-kala azar dermal leishmaniasis
por: Lacey, Charles, et al.
Publicado: (2022)

Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients
por: Verrest, Luka, et al.
Publicado: (2021)

Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial
por: Musa, Ahmed M, et al.
Publicado: (2022)

The Leishmaniasis East Africa Platform (LEAP): strengthening clinical trial capacity in resource-limited countries to deliver new treatments for visceral leishmaniasis
por: Wasunna, Monique, et al.
Publicado: (2016)

Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis
por: Kip, Anke E., et al.
Publicado: (2018)

Visceral Leishmaniasis and HIV Coinfection: Time for Concerted Action
por: van Griensven, Johan, et al.
Publicado: (2014)

Visceral Leishmaniasis Associated with HIV Coinfection in Pará, Brazil
por: Camargo Júnior, Raimundo Nonato Colares, et al.
Publicado: (2023)

Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients
por: Adriaensen, Wim, et al.
Publicado: (2018)

Elevated TGF-beta levels in drug-resistant visceral leishmaniasis
por: Elmekki, Miskelyemen A., et al.
Publicado: (2016)

Leishmaniasis and AIDS coinfection
por: Hozannah, Adriana, et al.
Publicado: (2013)

Visceral leishmaniasis and COVID-19 coinfection – A case report
por: Pikoulas, Antonis, et al.
Publicado: (2021)

Severe visceral leishmaniasis and COVID-19 coinfection in an immunosuppressed patient
por: Martins, Luciamáre Perinetti Alves, et al.
Publicado: (2022)

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial
por: Wasunna, Monique, et al.
Publicado: (2016)

In Silico Evaluation of the Potential Association of the Pathogenic Mutations of Alpha Synuclein Protein with Induction of Synucleinopathies
por: Elnageeb, Mohamed E., et al.
Publicado: (2023)

Cutaneous Leishmaniasis: Associated Risk Factors and Prevention in Hubuna, Najran, Saudi Arabia
por: Alzahrani, Mohammed Jamaan, et al.
Publicado: (2023)

Prevalence of Cutaneous Leishmaniasis in Western Highlands in Yemen
por: Alkulaibi, Mohammed Musid, et al.
Publicado: (2019)

Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme
por: Kimutai, Robert, et al.
Publicado: (2017)

Factors associated with relapse and hospital death in patients coinfected with visceral leishmaniasis and HIV: a longitudinal study
por: Costa, Larissa D. L. N., et al.
Publicado: (2023)

Visceral Leishmaniasis, Northern Somalia, 2013–2019
por: Aalto, Mikko K., et al.
Publicado: (2020)

Tegumentary leishmaniasis and coinfections other than HIV
por: Martínez, Dalila Y., et al.
Publicado: (2018)

Visceral Leishmaniasis: New Health Tools Are Needed
por: Hailu, Asrat, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_07bskdr0pqek1h41ok2900hs85